Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.

•Nivolumab + ipilimumab improved patient-reported outcomes versus chemotherapy in non–small-cell lung cancer.•Improvements were seen in lung cancer symptoms and in general health status.•Improvements with nivolumab + ipilimumab were rapid and durable.•Disease-related symptom deterioration was delayed with nivolumab + ipilimumab.